Subsets of T Cells in the Immunopathogenesis and Management of Sjogren's syndrome

Edzard Sullivan^*
*Correspondence: Edzard Sullivan, Department of Integrative Medicine, Universities of Exeter, Exeter, UK, Email:

Introduction

Sjogren's Syndrome (SS) is a complex autoimmune disorder characterized by chronic inflammation of exocrine glands, leading to dryness of mucosal surfaces, particularly the eyes and mouth. The pathogenesis of SS involves intricate immune dysregulation, with T cells playing a central role. This article delves into the subsets of T cells implicated in the immunopathogenesis of Sjogren's syndrome and explores their potential as therapeutic targets. A comprehensive review of current research on T cell involvement in SS provides insights into the molecular mechanisms underlying the disease. Additionally, the article discusses emerging therapeutic strategies targeting T cell subsets to manage SS effectively [1]. Sjogren's Syndrome (SS) is a chronic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, leading to dryness of mucosal surfaces, most notably the eyes and mouth. The immunopathogenesis of SS is multifaceted, involving a complex interplay of immune cells and molecular pathways. Among these, T cells emerge as key orchestrators of the inflammatory cascade. This article explores the subsets of T cells implicated in the immunopathogenesis of Sjogren's syndrome, shedding light on their roles and potential as therapeutic targets. Additionally, emerging strategies for managing SS by modulating T cell responses will be discussed.

Description

The immunopathogenesis of Sjogren's syndrome involves a series of intricate events that ultimately result in the destruction of exocrine glands. T cells, a crucial component of the adaptive immune system, play a central role in orchestrating the immune response in SS. CD4+ T cells, commonly known as helper T cells, are integral to the immune response and have been implicated in the pathogenesis of SS. In SS patients, there is an abnormal activation of CD4+ T cells, leading to infiltration of exocrine glands. These activated CD4+ T cells release pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha, contributing to local inflammation and tissue damage. Moreover, CD4+ T cells differentiate into specialized subsets, such as Th1 and Th17 cells, which are known to play a role in autoimmune diseases. Th1 cells release interferon-gamma, promoting inflammation, while Th17 cells produce IL-17, contributing to tissue damage. The dysregulation of these CD4+ T cell subsets in SS amplifies the inflammatory response, further compromising glandular function [2].

CD8+ T cells, also known as cytotoxic T cells, are crucial for eliminating infected or damaged cells. In SS, there is evidence of increased infiltration of CD8+ T cells into the affected glands. These cytotoxic T cells recognize and destroy glandular cells, exacerbating tissue damage. The activation of CD8+ T cells in SS may be triggered by autoantigens, leading to the formation of cytotoxic effector cells. Additionally, the sustained activation of CD8+ T cells may contribute to a chronic inflammatory milieu, perpetuating the autoimmune response in SS. In contrast to effector T cells, regulatory T cells (Tregs) play a suppressive role in the immune system, maintaining immune tolerance and preventing excessive inflammation. Tregs are crucial for modulating the immune response and preventing autoimmunity. In Sjogren's syndrome, there is evidence of reduced Treg function, leading to an imbalance between regulatory and effector T cells. This dysregulation contributes to the perpetuation of inflammation and tissue damage in affected glands [3].

Understanding the molecular mechanisms driving T cell dysregulation in Sjogren's syndrome is essential for developing targeted therapeutic interventions. Several molecular pathways contribute to the aberrant activation and function of T cells in SS. Abnormal cytokine signaling is a hallmark of SS. Elevated levels of pro-inflammatory cytokines, such as IL-6, IL-17, and TNF-α, contribute to the activation and survival of pathogenic T cell subsets. Targeting these cytokine pathways has shown promise as a therapeutic approach in managing SS. The identification of specific autoantigens in SS, such as Ro (SSA) and La (SSB), has provided insights into the molecular triggers of the autoimmune response. Molecular mimicry, where microbial antigens share similarity with self-antigens, may initiate and perpetuate T cell responses in SS. Understanding these molecular interactions can guide the development of antigen-specific therapies [4].

Epigenetic changes, including DNA methylation and histone modifications, play a role in shaping T cell responses in SS. Altered epigenetic profiles in T cells contribute to their aberrant activation and differentiation. Targeting epigenetic modifications presents a novel avenue for therapeutic intervention. The complex interplay of T cell subsets and molecular pathways in SS necessitates a multi-faceted approach to therapeutic intervention. Several potential targets have emerged, aiming to modulate T cell responses and restore immune balance in SS. Targeting specific cytokines, such as IL-6 and IL-17, with monoclonal antibodies or small molecule inhibitors has shown promise in ameliorating inflammation in SS. Clinical trials investigating the efficacy of cytokine inhibitors in SS are underway, offering hope for targeted immunomodulation. Strategies to modulate T cell responses directly are being explored. This includes the use of immunomodulatory drugs that target T cell activation and differentiation pathways. Additionally, therapies aimed at restoring the balance between effector and regulatory T cells hold potential for managing SS [5].

Conclusion

Collaborative efforts between immunologists, rheumatologists, molecular biologists, and clinicians are essential for advancing our understanding of T cell subsets in SS. Multidisciplinary research endeavors can expedite the translation of discoveries into clinical applications. In conclusion, T cells play a pivotal role in the immunopathogenesis of Sjogren's syndrome. Understanding the subsets of T cells involved, their molecular underpinnings, and potential therapeutic targets opens new avenues for managing this complex autoimmune disorder. As research advances, the translation of these insights into clinically viable interventions holds promise for improving the quality of life for individuals with Sjogren's syndrome. Ongoing collaboration and continued exploration of T cell subsets in SS are essential for the development of targeted and effective therapies that address the underlying immunopathology of this autoimmune condition.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Kumar, Brahma V., Thomas J. Connors and Donna L. Farber. "Human T cell development, localization and function throughout life." Immun 48 (2018): 202-213.

   Google Scholar, Crossref, Indexed at

2. Fessler, Johannes, Patrizia Fasching, Andrea Raicht and Sabrina Hammerl, et al. "Lymphopenia in primary Sjögren’s syndrome is associated with premature aging of naïve CD4+ T cells." Rheumatol 60 (2021): 588-597.

   Google Scholar, Crossref, Indexed at

3. Felten, Renaud, Florence Scher, Jean Sibilia and Jacques-Eric Gottenberg, et al. "The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials." Autoimmun Rev 18 (2019): 576-582.

   Google Scholar, Crossref, Indexed at

4. Imgenberg-Kreuz, Juliana, Astrid Rasmussen, Kathy Sivils and Gunnel Nordmark. "Genetics and epigenetics in primary Sjögren’s syndrome." Rheumatol 60 (2021): 2085-2098.

   Google Scholar, Crossref, Indexed at

5. Macian, Fernando. "Autophagy in T cell function and aging." Front Cell Develop Biol 7 (2019): 213.

   Google Scholar, Crossref, Indexed at